



- (51) International Patent Classification:
A01N 43/54 (2006.01)
- (21) International Application Number:
PCT/US2013/030996
- (22) International Filing Date:
13 March 2013 (13.03.2013)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/611,400 15 March 2012 (15.03.2012) US
- (71) Applicant: **CELGENE AVILOMICS RESEARCH, INC.** [US/US]; 45 Wiggins Avenue, Bedford, MA 01730 (US).
- (72) Inventors: **LAI, Mei**; 1038 Neon Forest Circle, Longmont, CO 80504 (US). **WITOWSKI, Steven, Richard**; 171 Laurel Street, Melrose, MA 02176 (US). **TESTER, Richard, Wayne**; 23 Gregoire Drive, Marlborough, MA 01752 (US). **LEE, Kwangho**; 22 Middlesex Circle #7, Waltham, MA 02452 (US).
- (74) Agents: **BUTEAU, Kristen, C.** et al.; Choate, Hall & Stewart LLP, Two International Place, Boston, MA 02110 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR

(57) Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.

